Martha Torres, Lourdes García-García, Pablo Cruz-Hervert, Heinner Guio, Claudia Carranza, Leticia Ferreyra-Reyes, Sergio Canizales, Susana Molina, Elizabeth Ferreira-Guerrero, Norma Téllez, Rogelio Montero-Campos, Guadalupe Delgado-Sánchez, Norma Mongua-Rodriguez, Jose Sifuentes-Osornio, Alfredo Ponce-de Leon, Eduardo Sada, Douglas B Young, Robert J Wilkinson
Journal: The European respiratory journal 2016;45(2):473-82
PMID: 25359354
Treatment of persons with latent tuberculosis (TB) infection at greatest risk of reactivation is an important component of TB control and elimination strategies. Biomarkers evaluating the effectiveness of treatment of latent TB infection have not yet been identified. This information would enhance control efforts and assist the evaluation of new treatment regimes. We designed a two-group, two-arm, randomised clinical study of tuberculin skin test-positive participants: 26 with documented contact with TB patients and 34 with non-documented contact. Participants in each group were randomly assigned to the immediate- or deferred-isoniazid treatment arms. Assays of in vitro interferon (IFN)-γ secretion in response to recombinant Rv1737 and overlapping synthetic peptide pools from various groups of immunodominant proteins were performed. During isoniazid therapy, a significant increase from baseline in the proportion of IFN-γ responders to the 10-kDa culture filtrate protein, Rv2031, Rv0849, Rv1986, Rv2659c, Rv2693c and the recombinant Rv1737 protein was observed (p⩽0.05). The peptide pool of Rv0849 and Rv1737 recombinant proteins induced the highest percentage of IFN-γ responders after isoniazid therapy. The in vitro IFN-γ responses to these proteins might represent useful markers to evaluate changes associated with treatment of latent TB infection.
Copyright ©ERS 2015.
Full Text Sources:
Medical:
Other Literature Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.